Microbot Medical Business Summary

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial-stage medical device company that generates revenue through a B2B model centered on the sale of its proprietary LIBERTY Endovascular Robotic System and recurring sales of its associated single-use disposables. The company’s business is primarily segmented into advanced endovascular robotics and micro-robotic technologies, including the LIBERTY and NovaCross platforms. Unlike traditional surgical robotics that require high capital expenditure (CAPEX) and dedicated catheterization labs, Microbot’s model focuses on a fully disposable, remotely operated architecture designed to lower the barrier to entry for hospitals and clinics. In the competitive landscape, Microbot contends with established players such as Siemens Healthineers (Corindus CorPath GRX), Stereotaxis (Genesis RMN), and Robocath (R-One). Microbot distinguishes itself as the provider of the world’s first FDA-cleared, single-use endovascular robot, positioning its technology as a more portable, cost-effective, and radiation-reducing alternative to the heavy-infrastructure systems of its peers. The company was co-founded by Harel Gadot, Professor Moshe Shoham, and Yossi Bornstein. Harel Gadot serves as the current President, CEO, and Chairman, bringing a pedigree from Johnson & Johnson (Ethicon) and MEDX Ventures Group. Co-founder Moshe Shoham is a renowned robotics pioneer who previously founded Mazor Robotics (acquired by Medtronic for $1.6 billion). The executive team is further bolstered by CTO Simon Sharon, a veteran of the medical device industry with over 30 years of experience, and CFO Rachel Vaknin. The company’s board includes seasoned directors such as Scott Burell and Martin Madden, with notable institutional backing from investors including Vanguard Group, Heights Capital Management, and CIBC Bancorp. This leadership team combines deep clinical expertise with a track record of successful exits in the surgical robotics and medical technology sectors.